GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » Cyclically Adjusted Book per Share

Kintara Therapeutics (Kintara Therapeutics) Cyclically Adjusted Book per Share : $-28.15 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Kintara Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $-1.024. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-28.15 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 11.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Kintara Therapeutics was 11.50% per year. The lowest was 11.50% per year. And the median was 11.50% per year.

As of today (2024-05-15), Kintara Therapeutics's current stock price is $0.1329. Kintara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $-28.15. Kintara Therapeutics's Cyclically Adjusted PB Ratio of today is .


Kintara Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Kintara Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Cyclically Adjusted Book per Share Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -43.53 -45.54 -49.50 -30.18

Kintara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.55 -46.12 -30.18 -29.98 -28.15

Competitive Comparison of Kintara Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Kintara Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Cyclically Adjusted PB Ratio falls into.



Kintara Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kintara Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.024/129.4194*129.4194
=-1.024

Current CPI (Dec. 2023) = 129.4194.

Kintara Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 -190.773 99.695 -247.654
201406 0.000 100.560 0.000
201409 13.138 100.428 16.931
201412 93.727 99.070 122.440
201503 47.542 99.621 61.763
201506 -55.753 100.684 -71.665
201509 -40.223 100.392 -51.853
201512 -7.314 99.792 -9.485
201603 -43.657 100.470 -56.236
201606 -84.226 101.688 -107.195
201609 -125.313 101.861 -159.216
201612 -180.707 101.863 -229.593
201703 -224.368 102.862 -282.296
201706 5.307 103.349 6.646
201709 143.927 104.136 178.872
201712 78.704 104.011 97.930
201803 26.953 105.290 33.130
201806 -21.555 106.317 -26.239
201809 -59.805 106.507 -72.671
201812 -64.582 105.998 -78.852
201903 -93.585 107.251 -112.929
201906 -39.198 108.070 -46.942
201909 9.740 108.329 11.636
201912 2.970 108.420 3.545
202003 -4.739 108.902 -5.632
202006 -19.816 108.767 -23.579
202009 -5.324 109.815 -6.274
202012 -8.213 109.897 -9.672
202103 -5.679 111.754 -6.577
202106 -6.643 114.631 -7.500
202109 5.720 115.734 6.396
202112 1.327 117.630 1.460
202203 -3.213 121.301 -3.428
202206 -0.579 125.017 -0.599
202209 -1.817 125.227 -1.878
202212 -2.497 125.222 -2.581
202303 -4.054 127.348 -4.120
202306 -5.859 128.729 -5.890
202309 -7.236 129.860 -7.211
202312 -1.024 129.419 -1.024

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Kintara Therapeutics  (NAS:KTRA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Kintara Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (Kintara Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Executives
Robert Hoffman director, officer: President and CEO ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill officer: Chief Financial Officer 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian director, officer: Head of Strategic Partnerships P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr director 543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown officer: Chief Scientific Officer 100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos director, officer: SVP, Business Development 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell director 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara director 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston director 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr director 8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha director SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010